KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Weighted Average) (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $89.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 6.6% to $89.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.9 million through Dec 2025, up 6.6% year-over-year, with the annual reading at $89.9 million for FY2025, 6.6% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $89.9 million in Q4 2025 for CRISPR Therapeutics AG, up from $88.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $89.9 million in Q4 2025 to a low of $75.0 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $80.8 million across 5 years, with a median of $79.0 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 23.45% in 2021 and later rose 1.65% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $75.9 million in 2021, then grew by 2.37% to $77.7 million in 2022, then increased by 1.9% to $79.2 million in 2023, then grew by 6.49% to $84.4 million in 2024, then grew by 6.6% to $89.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRSP at $89.9 million in Q4 2025, $88.1 million in Q3 2025, and $87.1 million in Q2 2025.